Payment overview · 2025
General Payments
$3,135.61
28 reported records · 10 companies
Healthcare provider profile · identity verified
Usman A Cheema, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · GALESBURG, IL · NPI 1518071760
Verified facts
What the public records show
CMS Open Payments records show Usman A Cheema, MD received $3,135.61 in general payments during 2025 across 28 reported records.
INTUITIVE SURGICAL, INC. accounted for 37.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Nucala, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ofev by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Nucala by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 695 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $1,167.78 | 37.2% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $763.71 | 24.4% | 7 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $238.17 | 7.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $207.47 | 6.6% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $152.27 | 4.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $147.62 | 4.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $123.40 | 3.9% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $120.83 | 3.9% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $108.77 | 3.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $105.59 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,996.28 | 22 |
| Travel and Lodging | $1,139.33 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $1,167.78 | 7 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $346.94 | 3 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $239.30 | 2 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $203.98 | 2 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $165.07 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $152.27 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $124.89 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $123.40 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $122.29 | 1 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $120.83 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $119.89 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $117.16 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $105.59 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $3.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 58 | exact normalized | Medicare Part D |
| NUCALA nucala |
2025 | Nucala | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 695 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
71 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
175 | 67 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
695 | 162 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 695 | 162 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 487 | 176 |
| Azithromycin | Azithromycin | 466 | 165 |
| Prednisone | Prednisone | 440 | 153 |
| Montelukast Sodium | Montelukast Sodium | 385 | 97 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 303 | 85 |
| Spiriva Respimat | Tiotropium Bromide | 227 | 54 |
| Roflumilast | Roflumilast | 209 | 46 |
| Furosemide | Furosemide | 207 | 53 |
| Losartan Potassium | Losartan Potassium | 194 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 187 | 44 |
| Potassium Chloride | Potassium Chloride | 181 | 52 |
| Eliquis | Apixaban | 176 | 31 |
| Symbicort | Budesonide/Formoterol Fumarate | 175 | 67 |
| Ventolin Hfa | Albuterol Sulfate | 170 | 63 |
| Gabapentin | Gabapentin | 164 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 156 | 34 |
| Atorvastatin Calcium | Atorvastatin Calcium | 154 | 39 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 153 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 151 | 30 |
| Breo Ellipta | Fluticasone/Vilanterol | 148 | 35 |
| Alprazolam | Alprazolam | 147 | 24 |
| Lisinopril | Lisinopril | 133 | 33 |
| Amlodipine Besylate | Amlodipine Besylate | 132 | 35 |
| Metformin Hcl | Metformin Hcl | 120 | 29 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 117 | 40 |
| Spironolactone | Spironolactone | 114 | 29 |
| Methylprednisolone | Methylprednisolone | 112 | 98 |
| Omeprazole | Omeprazole | 112 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 111 | 34 |
| Sertraline Hcl | Sertraline Hcl | 107 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 97 | 69 |
| Allopurinol | Allopurinol | 93 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 87 | 16 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 85 | 17 |
| Incruse Ellipta | Umeclidinium Bromide | 83 | 22 |
| Tramadol Hcl | Tramadol Hcl | 80 | 24 |
| Xarelto | Rivaroxaban | 80 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 77 | 16 |
| Alendronate Sodium | Alendronate Sodium | 74 | 21 |
| Simvastatin | Simvastatin | 74 | 18 |
| Meloxicam | Meloxicam | 72 | 23 |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 71 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 23 |
| Warfarin Sodium | Warfarin Sodium | 67 | suppressed |
| Dulera | Mometasone/Formoterol | 66 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 15 |
| Valsartan | Valsartan | 63 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 61 | suppressed |
| Jardiance | Empagliflozin | 58 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 53 | 21 |
| Ofev | Nintedanib Esylate | 51 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 47 | 23 |
| Famotidine | Famotidine | 47 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 45 | 19 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 45 | suppressed |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | suppressed |
| Lovastatin | Lovastatin | 38 | 11 |
| Nifedipine Er | Nifedipine | 38 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 37 | 14 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 37 | 13 |
| Glipizide | Glipizide | 35 | suppressed |
| Carvedilol | Carvedilol | 33 | 11 |
| Finasteride | Finasteride | 33 | suppressed |
| Lorazepam | Lorazepam | 33 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 17 |
| Arnuity Ellipta | Fluticasone Furoate | 29 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Nystatin | Nystatin | 29 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Cefdinir | Cefdinir | 28 | 24 |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Nucala | Mepolizumab | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Budesonide | Budesonide | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Klor-Con 10 | Potassium Chloride | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 17 |
| Olanzapine | Olanzapine | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Fasenra Pen | Benralizumab | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Dexamethasone | Dexamethasone | 22 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Azathioprine | Azathioprine | 20 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | 19 |
| Celecoxib | Celecoxib | 19 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 19 | 11 |
| Metolazone | Metolazone | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Dupixent Pen | Dupilumab | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Itraconazole | Itraconazole | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 15 |
| Fosinopril Sodium | Fosinopril Sodium | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 17 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 15 |
| Albuterol Sulfate | Albuterol Sulfate | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Fluticasone-Salmeterol Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Dupixent Syringe | Dupilumab | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Theo-24 | Theophylline Anhydrous | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Hyoscyamine Sulfate | Hyoscyamine Sulfate | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,135.61 · 28 records | INTUITIVE SURGICAL, INC. | AIRSUPRA, BREZTRI, DUPIXENT, Da Vinci Surgical System, EVENITY, FARXIGA, FASENRA, JARDIANCE, NUCALA, Ohtuvayre, Ozempic, Prolastin-C Liquid, TEZSPIRE, TRELEGY ELLIPTA, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error